Compare Inovio Pharmaceuticals Inc (INO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Oatly Group AB - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Oatly Group AB - ADR is far larger — about 2.9× Inovio Pharmaceuticals Inc's market cap, and Oatly Group AB - ADR is more actively traded (68,708 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Oatly Group AB - ADR for 18 Days on average.
| INO | OTLY | |
|---|---|---|
Market Cap | $112.19M | $330.93M |
Volume | 3,201,278 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $2.60 | $15.91 |
52-Week Low | $0.66 | $8.03 |
Typical Hold Time | 43 Days | 18 Days |
Enterprise Value | $83.51M | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
OTLY trades at $10.38, up 0.1% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, showing progress toward profitability. The stock is supported by a consensus price target of $12.28 and positive news around Q2 2026 results, including a raised revenue outlook.
The outlook is cautiously optimistic as cost controls and sales growth may lead to positive EBITDA, but high debt and persistent cash burn pose risks. Analyst sentiment is mixed with 44% buy ratings, reflecting belief in the turnaround story amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
